ID
14001
Description
the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient; ODM derived from: https://clinicaltrials.gov/show/NCT01766375
Link
https://clinicaltrials.gov/show/NCT01766375
Keywords
Versions (1)
- 3/21/16 3/21/16 -
Uploaded on
March 21, 2016
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Acute Myeloid Leukemia NCT01766375
Eligibility Acute Myeloid Leukemia NCT01766375
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Description
Infection
Data type
boolean
Alias
- UMLS CUI [1]
- C3714514
Description
Idarubicin
Data type
boolean
Alias
- UMLS CUI [1]
- C0020789
Description
Anthracycline Antibiotics
Data type
boolean
Alias
- UMLS CUI [1]
- C0003234
Description
Inclusion criteria
Data type
boolean
Alias
- UMLS CUI [1]
- C2827031
Description
Withdrawal
Data type
integer
Alias
- UMLS CUI [1]
- C2349954
Similar models
Eligibility Acute Myeloid Leukemia NCT01766375
- StudyEvent: Eligibility
C0232804 (UMLS CUI [2])